Targeted Radionuclide Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (10 November 2021) | Viewed by 82521
Special Issue Editor
Interests: nuclear medicine; theranostics; molecular imaging; bioorthogonal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Identification of the molecular alterations involved in carcinogenesis has opened up new opportunities for personalized treatment of cancer patients, such as targeted radionuclide therapy. From the early 1990s, targeted radionuclide therapy has received tremendous attention due to the encouraging (pre)clinical results obtained with radiotherapeutics combining a targeting vector (i.e., small molecules, peptides, antibodies) and a cytotoxic radionuclide. A broad variety of radiotherapeutics has been successfully developed to eradicate specifically cancer cells, leading to the recent FDA and EMA registration of a radiolabeled drug for the treatment of neuroendocrine tumors; but many other novel radiopharmaceuticals hold enormous potential for future applications. However, challenges remain and can eventually be overcome by diverse strategies. Hence, the development of new generation of radiopharmaceuticals with improved therapeutic efficacy holds great promise. Production of novel therapeutic radionuclide, targeted alpha therapy (TAT), modification of the pharmacokinetic profile of the radiotherapeutics, bioorthogonal labeling and pretargeting are examples of major research directions, which will be highlighted in this Special Issue of Pharmaceutics on "Targeted Radionuclide Therapy". Original research papers, communications, or review articles are welcome for this Special Issue.
Dr. Yann Seimbille
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Radionuclide therapy
- Theranostics
- Cancer
- Labeling chemistry
- In vitro and in vivo characterization
- Targeted alpha therapy
- Pretargeting
- Dosimetry
- Radiobiology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.